Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 82. CrossRef
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment Mark Sulkowski, Laura E. Telep, Massimo Colombo, Francois Durand, K. Rajender Reddy, Eric Lawitz, Marc Bourlière, Nelson Cheinquer, Stacey Scherbakovsky, Liyun Ni, Lindsey Force, Heribert Ramroth, Anuj Gaggar, Anand P. Chokkalingam, Meghan E. Sise Alimentary Pharmacology & Therapeutics.2022; 55(9): 1169. CrossRef
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1. CrossRef
An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy Guglielmo Borgia, Riccardo Scotto, Antonio Riccardo Buonomo Expert Opinion on Investigational Drugs.2019; 28(5): 395. CrossRef
Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection Riccardo Scotto, Antonio Riccardo Buonomo, Nicola Schiano Moriello, Alberto Enrico Maraolo, Emanuela Zappulo, Biagio Pinchera, Ivan Gentile, Guglielmo Borgia Reviews on Recent Clinical Trials.2019; 14(3): 173. CrossRef
Lamivudine: fading into the mists of time Jonggi Choi, Young-Suk Lim Clinical and Molecular Hepatology.2017; 23(4): 314. CrossRef
Jeong Ihn Seo, M.D., Soon Koo Baik, M.D., Jae Woo Kim, M.D.,
Dae Wook Rhim, M.D., Yong Soon Park, M.D., Hyun Soo Kim, M.D.,
Dong Ki Lee, M.D., Sang Ok Kwon, M.D., and Sei Jin Chang, Ph.D.*
Background/Aims Renal dysfunction commonly develops in patients with established liver disease. The assessment of renal function is of clinical importance in patients with cirrhosis and ascites. Renal function indices such as glomerular filtration rate and the plasma renin activity (PRA) could be better predictors of survival than the parameters usually used to estimate liver function including Child-Pugh score. This study was designed to find whether renal function indices are useful in determining the prognosis concerned with the survival of patients with liver cirrhosis.Methods:A total of 110 patients was selected and followed for 89 weeks. As indices reflecting renal function, creatinine clearance rate, PRA, aldosterone concentration, and the pulsatility index (PI) and resistive index (RI) by Doppler ultrasonography were measured. The prognostic values of these indices were determined by comparison and analysis according to survival or death of the patients. For the statistics, univariate and multivariate analysis was done.Results:Child-Pugh score (≥10), creatinine clearance rate (<80 mL/min), plasma alodosterone concentration (≥15 ng/dL), PRA (≥8 ng/mL/hr), renal PI (≥1.15) and RI (≥0.7) were prognostic indicators in univariate analysis (p<0.05). Multivariate analysis disclosed two independent survival predictors of creatinine clearance rate (<80 mL/min) (OR:5.37, 95% CI: 2.09-13.82) and plasma aldosterone concentration (≥15 ng/dL) (OR: 3.65, 95% CI: 1.09-12.18). Conclusion:Various renal function indices are closely related to the survival of patients with liver cirrhosis. Creatinine clearance rate and plasma aldosterone concentration are especially important prognostic factors in predicting the survival of patients with liver cirrhosis.(Korean J Hepatol 2001;7:140-146)